Buy Sun Pharmaceutical Industries Ltd for the Target Rs.350 by Choice Institutional Equities
Business Overview:
SUNP is India's largest pharmaceutical company and a leading global specialty pharma player, with a diversified portfolio spanning branded formulations, specialty therapies, generics, APIs and consumer healthcare. The company has built a strong presence across India, the US and Emerging Markets, driven by specialty products such as Ilumya, Cequa, Winlevi and Leqselvi. Backed by increasing investments in innovation, biologics and specialty therapies, along with the proposed Organon acquisition, SUNP is transitioning from a branded generics-led business to a globally diversified, innovation-driven pharmaceutical platform with expanding exposure to specialty and biosimilar products.
What is driving SUNP's transition into a global specialty pharmaceutical leader?
SUNP has successfully transformed from a branded generics-focused company into a global specialty pharma player, with innovative medicines crossing USD 1.1 Bn in US revenue during FY26. Growth is increasingly being driven by specialty products such as Ilumya, Cequa, Winlevi, Unloxcyt and Leqselvi, which offer superior margin and lower competitive intensity than traditional generics. This strategic shift is improving the quality of earnings while strengthening the company's global competitive positioning
How will the Organon acquisition reshape SUNP's growth trajectory?
The proposed Organon acquisition is expected to be transformational, significantly expanding SUNP's scale, strengthening its presence in biosimilars and increasing exposure to innovative products. The transaction is expected to diversify the revenue mix, enhance geographic reach, particularly in China and create new pipeline opportunities. The management expects the acquisition to close by Q4FY27, positioning the company for its next phase of growth beyond its existing specialty portfolio.
What supports SUNP's long-term growth outlook across key markets?
SUNP continues to gain market share in India through volume-led growth and product launches, including Semaglutide. In the US, specialty products are expected to drive high single-digit growth, while Emerging Markets are witnessing a gradual shift from branded generics to innovative therapies. Coupled with a robust specialty pipeline, lifecycle expansions for existing brands and increasing R&D investments, the company remains well positioned to deliver sustainable double-digit growth over the medium term.
Why Invest in SUNP?
* Transformational Organon Acquisition (Global Scale + Women’s Health): SUNP has signed a ~USD 11.75 Bn deal to acquire Organon, marking one of the largest outbound pharma acquisitions by an Indian company. The deal significantly expands its global branded portfolio, especially in women’s health, biosimilars, and established medicines, while adding distribution across ~140 countries.
* Strong India Franchise + Chronic Therapy Leadership: The company continues to dominate India’s chronic therapy segments like cardiology, dermatology, and neurology, which are structurally higher growth than acute therapies.
Recommendation:
We currently have a ‘BUY’ rating on the stock with a target price of INR 2,300.
Key Risks:
* Elevated Leverage Post Acquisition: The Organon acquisition is expected to materially increase Sun Pharma’s debt burden, impacting balance sheet flexibility in the near term.
* Regulatory & US Pricing Pressure: A large share of revenues is still exposed to the US generics market, which remains highly competitive and subject to price erosion
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
